Cost-effectiveness of insulin glargine versus NPH insulin for the treatment of Type 2 diabetes mellitus, modeling the interaction between hypoglycemia and glycemic control in Switzerland

International Journal of Clinical Pharmacology and Therapeutics

Volumn 49, Issue 3, 2011, Pages 217-230

  Brandle M ^a   Azoulay, M ^b   Greiner, R A ^c  

^a Kantonsspital Lucerne   (Switzerland)

^b Sanofi Aventis (Suisse) Sa   (Switzerland)

^c Health Economics Consultant   (Germany)

Author keywords

Cost effectiveness; Cost utility; Hypoglycemia; Insulin glargine; NPH insulin; Switzerland; Type 2 diabetes

Indexed keywords

HEMOGLOBIN A1C; INSULIN GLARGINE; ISOPHANE INSULIN; ORAL ANTIDIABETIC AGENT;

AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE SEVERITY; DISEASE SIMULATION; DRUG COST; DRUG EFFICACY; FEMALE; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; ISCHEMIC HEART DISEASE; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PREDICTION; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SENSITIVITY ANALYSIS; SWITZERLAND;

AGED; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, NPH; MALE; MIDDLE AGED; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS; SWITZERLAND; TIME FACTORS; TREATMENT OUTCOME;

EID: 79952224755     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP49217     Document Type: Article

References (59)

1. American Diabetes Association. Standards of Medical care in Diabetes. Diabetes Care. 2009; 32: 13-61.
2. DCCT; The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329: 977-986.
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352: 837-853.
4. Currie CJ, Morgan CL, Poole CD, Sharplin P, Lammert M, McEwan P. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin. 2006; 8: 1523-1534. (Pubitemid 44297431)
5. Cryer PE. Hypoglycaemia: The limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia. 2002; 45: 937-948. (Pubitemid 34762188)
6. Korytkowski M. When oral agents fail: Practical barriers to starting insulin. Int J Obes Relat Metab Disord. 2002; 26: 18-24.
7. Winocour PH. Effective diabetes care: a need for realistic targets. BMJ. 2002; 324: 1577-1580. (Pubitemid 34713140)
8. Gerstein HC et al. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358: 2545-2559.
9. Kahn S. Glucose control in type 2 diabetes: Still worthwhile and worth pursuing. JAMA. 2009; 301: 1590-1592.
10. Bonds DE et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ. 2010; 340: b4909 doi:10.1136/bmj.b4909.
11. Pieber TR, Eugene-Jolchine I, Derobert E. Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes. Diabetes Care. 2000; 23: 157-162.
12. Raskin P, Klaff L, Bergenstal R, Hallé JP, Donley D, Mecca T. A 16-week comparison of the novel insulin analog Lantus (HOE901) and NPH human insulin with insulin lispro inpatients with type 1 diabetes. Diabetes Care. 2000; 23: 1666-1671.
13. Home PD, Rosskamp R, Forjanic-Klapproth J, Dressler A. A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes. Diabetes Metab Res Rev. 2005; 21: 545-553. (Pubitemid 41646014)
14. Schober E, Schoenle E, Van Dyk J, Wernicke-Panten K. Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 2002; 15: 369-376. (Pubitemid 34704801)
15. Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA. Less hypoglycaemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care. 2000; 5: 639-643. (Pubitemid 30321544)
16. Rosenstock J, Park G, Zimmerman J. Basal Lantus (HOE901) versus NPH insulin in patients with type 1 diabetes or multiple daily insulin regimens. Diabetes Care. 2000; 23: 1137-1142. (Pubitemid 30616802)
17. Rosenstock J et al. Basal insulin therapy in Type 2 diabetes 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care. 2001; 24: 631-636. (Pubitemid 32888839)
18. Yki-Jarvinen H et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMETstudy. Diabetologia. 2006; 49: 442-451. (Pubitemid 43277866)
19. Riddle MC, Rosenstock J, Gerich J. Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003; 11: 3080-3086.
20. Horvath K et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2. Art. No.: CD005613. DOI: 10.1002/14651858.CD005613.pub3 (2007).
21. Fulcher GR, Gilbert RE, Yue DK. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy. Internal Medicine Journal. 2005; 35: 536-542. (Pubitemid 41291382)
22. Rossetti P et al. Intensive replacement of basal insulin in patients with type 1 diabetes given rapidacting insulin analog at mealtime. Diabetes Care. 2003; 26: 1490-1496.
23. Porcellati F et al. Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin. Diabet Med. 2004; 21: 1213-1220. (Pubitemid 39472377)
24. Murphy NP et al. Randomized crossover trial comparing insulin glargine plus insulin lispro with NPH insulin plus soluble insulin in adolescents with type 1 diabetes. Diabetologia. 2002; 45: 871.
25. Fritsche A, Schweitzer MA, Häring HU. Improved glycaemic control and reduced nocturnal hypoglycaemia in patients with type 2 diabetes with morning administration of insulin glargine compared with NPH insulin. Diabetes Care. 2002; 51: 149.
26. Mullins P, Sharplin P, Yki-Jarvinen H, Riddle MC, Häring HU. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus. Clin Ther. 2007; 29: 1607-1619. (Pubitemid 47496243)
27. Brändle M, Azoulay M, Greiner RA. Cost-effectiveness and cost-utility of insulin glargine compared with NPHinsulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland. Int J Clin Pharmacol Ther. 2007; 4: 203-220. (Pubitemid 46629383)
28. Schmitt-Koopmann I, Schwenkglenks M, Spinas GA, Szucs TD. Direct medical costs of type 2 diabetes and its complications in Switzerland. Eur J Public Health. 2004; 14: 3-9. (Pubitemid 38523652)
29. Poole CD, Tetlow T, McEwan P, Holmes P, Craig CJ. The prescription cost of managing people with type 1 and type 2 diabetes following initiation of treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis. Curr Med Res Opin. 2007; 23: 41-48.
30. Clarke PM et al. A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia. 2004; 47: 1747-1759.
31. McEwan P, Poole CD, Tetlow T, Holmes P, Craig CJ. Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 2 diabetes in the UK. Curr Med Res Opin. 2007; 23: 21-31.
32. Leese GP et al. Frequency of severe hypoglycaemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care. 2003; 26: 1176-1180. (Pubitemid 36929268)
33. HOE-901/4002. Target glycaemic control and the incidence of symptomatic nocturnal hypoglycaemia in insulin naïve subjects with Type 2 diabetes on oral hypoglycaemic agent(s) and treated with insulin glargine or NPH human insulin. Data on file, sanofi-aventis, Guildford, Surrey, UK, 2002 (accessed 2nd May, 2006).
34. Rosenstock J, Dailey G, Massi-Benedetti M, Fritsche A, Lin Z, Salzman A. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care. 2005; 4: 950-955. (Pubitemid 40434505)
35. Medical Research Matters Limited. Insulin glargine and insuslin detemir for type 1 and type 2 diabetes: systematic review of randomised controlled trials. Report for sanofi-aventis 2006 (data on file, sanofi-aventis, Guildford, Surrey, UK).
36. Fritsche A, Schweitzer MA, Häring HU. 4001 Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med. 2003; 138: 952-959.
37. Yki-Jarvinen H, Haring H, Zeger S, Arbet Engels C, Nguyen H, Riddle M. The relationship between HbA, fasting blood glucose (FBG), and hypoglycaemia using insulin glargine versus NPH insulin: a meta-regression analysis in type 2 diabetes (Abstract). Diabetes. 2003; 52 (Suppl): 149.
38. TARMED Suisse. Bern, Switzerland; 2009.
39. List of laboratory analyses. Federal Office of Public Health, Bern, Switzerland; 2009.
40. List of ergotherapeutic services. Swiss Association of Ergotherapists. Bern, Switzerland; 2009.
41. Mittel- und Gegenstände-Liste MiGel. Swiss Association of Orthopaedic Technicians (SVOT). Federal Office of Public Health, Bern, Switzerland; 2009.
42. APDRG Switzerland. Manual Cost weights and Swiss payment groups version 5.1. APDRG Swiss Group (Luc Schenker), Prilly, Switzerland; 2005.
43. Swiss hospital statistics. Swiss Federal Statistical Office, Neuchatel, Switzerland; 2006.
44. Statistics of the social medical institutions. Swiss Federal Statistical Office, Neuchatel, Switzerland; 2005.
45. List of pharmaceutical specialties. Federal Office of Public Health, Bern, Switzerland; 2006.
46. Intercontinental Marketing Services IMS Health. Hergiswil, Switzerland; 2007. Data on file, sanofiaventis, Meyrin, Switzerland.
47. Swiss Conference of Cantonal Ministers of Public Health. Bern, Switzerland; 2008.
48. Mattle HP, Eicher Vella E, Bassetti C, Sandercock P. International Stroke Trial Switzerland: some epidemiologic data. Schweiz Med Wochenschr. 1999; 50: 1964-1969. (Pubitemid 30012957)
49. Szucs TD et al. Gesundheitsökonomische Aspekte der chronischen Herzinsuffizienz. Schweiz Ärztezeitung. 2003; 84: 2431-2435.
50. Sandoz MS, Ess SM, Keusch GW, Schwenkglenks M, Szucs TD. Prevalence and direct medical costs of end-stage renal disease in patients with type 2 diabetes mellitus in Switzerland for 2001. Swiss Med Wkly. 2004; 134: 448-458.
51. Morgan CL, McEwan P, Morrissey M, Peters JR, Poole C, Currie CJ. Characterization and comparison of health-related utility in people with diabetes with various single and multiple vascular complications. Diabet Med. 2006; 23: 1100-1105. (Pubitemid 44401139)
52. Lee AJ, Morgan CLl, Conway P, Currie CJ. Characterisation and comparison of health-related quality of life for patients with renal failure. Curr Med Res Opinion. 2005; 21: 1777-1783. (Pubitemid 41667245)
53. National Institute for Clinical Excellence NICE. The guidelines manual - Chapter 8: Incorporating health economics in guidelines and assessing resource impact. 〈http://www.nice.org.uk/download.aspx?o=308777〉 (last accessed 20th June 2008).
54. Duckworth W et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009; 360: 129-139.
55. Jönsson L, Bolinder B, Lundkvist J. Cost of hypoglycemia in patients with Type2 diabetes in Sweden. Value Health. 2006; 9: 193-198.
56. Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med. 2003; 163: 1637-1641.
57. Hoey J. Experts disagree over NICE's approach for assessing drugs. Lancet. 2007; 370: 643-644.
58. Eichler HG, Kong SX, Gerth WC, Mavros P, Jönsson B. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health. 2004; 5: 518-528.
59. Grima DT, Thompson MF, Sauriol L. Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada. Pharmacoeconomics. 2007; 25: 253-266. (Pubitemid 46376834)